Chinese people's concerns about quality of locally made drugs are creating an opportunity for US firms says Gov

By Gareth Macdonald

- Last updated on GMT

Gettyimages/Golden_Brown
Gettyimages/Golden_Brown

Related tags United states Pharmacology

Chinese patients’ concerns about the quality of locally made drugs are an opportunity for US manufacturers to increase market share according to the US-China Economic and Security Review Commission.

The Commission – which reports to Congress on the national security implications of trade between the two countries – made the suggestion in a report​ this week also citing analysis​ by the US Department of Commerce.

Barriers to entry

The authors explained that although drugs are the US’ second largest and second fastest growing export to China – the value of pharmaceutical shipments increased from $402m in 2007 to $2.2bn in 2016 – the country still accounts for a relatively small amount of US sales.

In 2016 China was the second-largest pharmaceutical market globally, but only the ninth-largest export market for the United States, accounting for 4 percent of U.S. pharmaceutical preparation exports​” they said.

The authors attributed the disparity to barriers to entry that hamper US firms.

China uses an asynchronous review process to approve foreign pharmaceutical products that requires safety trials of foreign drugs to be at an advanced stage in other countries before Chinese regulators begin their own review process.

This significantly slows the introduction of new foreign drugs into China’s market, essentially doubling review times for foreign pharmaceuticals​” they said, adding that in some cases US drugs have been held up by as much as seven years.

Other barriers include the requirement that drugs are tested in China (a workaround for which was introduced in October​), the chronic shortage of Chinese regulatory staff as well as shortcomings in the country’s IP system.

Opportunity

Despite these hurdles, the authors suggest there are opportunities for US drug and active pharmaceutical ingredient (API) firms in China.

Chinese consumers may prefer US pharmaceutical products due to concerns over the quality of domestic drugs. China has been a prolific source of counterfeit and defective medicine​” according to the authors.

They cite the seizure of tainted gel capsules in 2012 ​as an example of issues that have damaged the reputation of China’s drug industry in China, also pointing to its reputation as a source for fake products as another factor.

According to the Office of the United States Trade Representative, in 2016, 90 percent of all counterfeit pharmaceuticals seized at the U.S. border were from China, Hong Kong, India, or Singapore.

Quality concerns may boost US pharmaceutical sales to China​” according to the Commission.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...